TRAX
First Tracks Biotherapeutics, Inc.Company with tickers: TRAX
CIK
2091349
CUSIP
337185102
Shares Outstanding
34,892,381
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $52,811,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $33,955,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-52,811,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-50,484,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | — | ||||
| EPS (Diluted) | — |